NCAPH2

Across TCGA pan-cancer cohorts, NCAPH2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NCAPH2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where NCAPH2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NCAPH2 is over-expressed in tumor, although a few such as THCA and PRAD show the opposite, repressed pattern.

KIRC, LIHC, and COAD are the cancer types where NCAPH2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NCAPH2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.825	<.001	12	view →
LIHC	Female	II,III,IV	+1.549	<.001	9	view →
COAD	Female	All	+0.958	<.001	8	view →
HNSC	Male	III,IV	+0.886	<.001	8	view →
STAD	Male	II,III,IV	+0.931	<.001	6	view →
THCA	All	All	−0.233	<.001	6	view →
CHOL	Male	All	+2.195	<.001	5	view →
BLCA	Female	All	+0.315	.020	5	view →
ESCA	All	All	+0.754	<.001	4	view →
KIRP	All	IV	+0.942	.010	2	view →
LUSC	Male	All	+0.500	<.001	2	view →
PRAD	All	All	−0.244	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NCAPH2–KIRC

Open the KIRC breakdown →